novartis (drug)

literal strings: novartis, NOVARTIS, Novartis

categories

NELL has only weak evidence for items listed in grey

• drug
• SEAL @139 (50.0%) on 27-jul-2010 [ 1 ] using novartis

relations

NELL has only weak evidence for items listed in grey

• agentcollaborateswithagent
• daniel_vasella
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (novartis, daniel_vasella)
• OE @964 (92.5%) on 13-dec-2015 [ http://online.wsj.com/news/articles/SB10001424052702303775504579394802939589802 http://www.swissinfo.ch/eng/business/Defensive_Vasella_regrets_tarnished_image.html?cid=35237512 http://www.swissinfo.ch/eng/business/Novartis_announces_final_pay-off_deal_for_Vasella.html?cid=36476660 http://www.bbc.co.uk/news/business-21504571 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.bloomberg.com/news/2013-07-17/novartis-to-pay-vasella-5-2-million-for-transition-work.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html http://www.philly.com/philly/blogs/phillypharma/78-million-golden-parachute-for-Novartis-Daniel-Vasella.html  ] using (daniel_vasella, novartis)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (novartis, daniel_vasella)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (novartis, daniel_vasella)
• SEAL @458 (50.0%) on 23-nov-2011 [ 1 ] using (daniel_vasella, novartis)
• CPL @1094 (96.9%) on 01-jan-2018 [ "arg1 Chairman and Chief Executive arg2" "arg1 Chairman and CEO arg2" "arg1 chairman arg2" "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols" "Y~_X0~concept:agentcontrols" "Y~_X0~concept:controlledbyagent" "Y~X0~concept:superpartof" ] using (daniel_vasella, novartis)
• dr_daniel_vasella
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (dr_daniel_vasella, novartis)
• CPL @1098 (75.0%) on 21-jan-2018 [ "arg1 chief executive arg2" "arg1 chairman and CEO arg2" ] using (novartis, dr_daniel_vasella)
• agentworkedondrug
• accupril
• SEAL @298 (50.0%) on 14-jun-2011 [ 1 ] using (accupril, novartis)
• aliskiren
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (aliskiren, novartis)
• OE @949 (88.3%) on 20-sep-2015 [ http://www.healio.com/cardiology/highlights-from-acc-scientific-sessions/astronaut-aliskiren-did-not-benefit-hospitalized-hf-patients http://www.pharmatimes.com/article/11-12-23/Novartis_aliskiren_under_European_review_following_safety_concerns.aspx http://cardiobrief.org/2011/12/20/altitude-study-of-aliskiren-terminated-early-by-novartis/  ] using (aliskiren, novartis)
• benazepril
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (benazepril, novartis)
• comtan
• SEAL @241 (87.5%) on 22-apr-2011 [ 1 2 3 ] using (comtan, novartis)
• CPL @1095 (75.0%) on 17-jan-2018 [ "arg2 for their drug arg1" "arg2 under the trade names arg1" ] using (comtan, novartis)
• cubicin
• SEAL @263 (75.0%) on 22-may-2011 [ 1 2 ] using (cubicin, novartis)
• denavir
• SEAL @560 (93.8%) on 03-may-2012 [ 1 2 3 4 ] using (denavir, novartis)
• diovan
• SEAL @221 (96.9%) on 18-mar-2011 [ 1 2 3 4 5 ] using (diovan, novartis)
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg2 under the trade name arg1" ] using (diovan, novartis)
• elidel
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg1 is manufactured and marketed by arg2" "arg1 marketed by arg2" "arg1 is marketed by arg2" ] using (elidel, novartis)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (elidel, novartis)
• exelon
• SEAL @236 (87.5%) on 16-apr-2011 [ 1 2 3 ] using (exelon, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" "arg1 is marketed by arg2" ] using (exelon, novartis)
• exforge
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (exforge, novartis)
• CPL @1113 (50.0%) on 03-aug-2018 [ "arg2 hypertension drug arg1" ] using (exforge, novartis)
• exforge_hct
• SEAL @263 (100.0%) on 22-may-2011 [ 1 2 3 ] using (exforge_hct, novartis)
• famciclovir
• OE @830 (100.0%) on 13-apr-2014 [   ] using (famciclovir, novartis)
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (famciclovir, novartis)
• famvir
• CPL @1098 (50.0%) on 21-jan-2018 [ "arg1 which is marketed by arg2" ] using (famvir, novartis)
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (famvir, novartis)
• femara
• SEAL @221 (99.6%) on 18-mar-2011 [ 1 2 3 4 5 6 7 8 ] using (femara, novartis)
• fluvastatin
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (fluvastatin, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.statinanswers.com/fluvastatin.htm http://www.ncbi.nlm.nih.gov/pubmed/11336101  ] using (fluvastatin, novartis)
• foradil
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is marketed by arg2" ] using (foradil, novartis)
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (foradil, novartis)
• gleevec
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (gleevec, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 a patent for arg1" "arg2 has secured access to arg1" ] using (gleevec, novartis)
• glivec
• CPL @1103 (75.0%) on 06-mar-2018 [ "arg2 has secured access to arg1" "arg2 a patent for arg1" ] using (glivec, novartis)
• SEAL @269 (87.5%) on 24-may-2011 [ 1 2 3 ] using (glivec, novartis)
• imatinib
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (imatinib, novartis)
• CPL @1104 (50.0%) on 18-mar-2018 [ "arg1 is marketed by arg2" ] using (imatinib, novartis)
• interceptor
• SEAL @878 (100.0%) on 10-oct-2014 [ 1 ] using (interceptor, novartis)
• lamisil
• CPL @1104 (50.0%) on 18-mar-2018 [ "arg2 employs some of arg1" ] using (lamisil, novartis)
• SEAL @236 (93.8%) on 16-apr-2011 [ 1 2 3 4 ] using (lamisil, novartis)
• lescol
• SEAL @221 (87.5%) on 18-mar-2011 [ 1 2 3 ] using (lescol, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg2 under the brand names arg1" "arg2 under the brand name arg1" ] using (lescol, novartis)
• lipitor
• SEAL @298 (50.0%) on 14-jun-2011 [ 1 ] using (lipitor, novartis)
• lucentis
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 by Genentech and arg2" "arg1 is marketed by arg2" ] using (lucentis, novartis)
• SEAL @325 (93.8%) on 30-jun-2011 [ 1 2 3 4 ] using (lucentis, novartis)
• nateglinide
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (nateglinide, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.trialresultscenter.org/DS157-Novartis%20brand%20of%20nateglinide%20clinical%20trials.htm http://en.wikipedia.org/wiki/Nateglinide http://www.drugs.com/mmx/nateglinide.html  ] using (nateglinide, novartis)
• nicotinell
• SEAL @269 (100.0%) on 24-may-2011 [ 1 2 ] using (nicotinell, novartis)
• octreotide
• SEAL @623 (100.0%) on 10-aug-2012 [ 1 2 ] using (octreotide, novartis)
• OE @949 (100.0%) on 20-sep-2015 [ http://www.ncbi.nlm.nih.gov/pubmed/22048969 http://www.bionity.com/en/octreotide.html http://www.healio.com/endocrinology/neuroendocrinology/news/print/endocrine-today/%7Bf90767ef-3047-4988-ae7e-cfa77bebefeb%7D/oral-octreotide-may-offer-new-option-for-patients-with-acromegaly http://www.rsc.org/chemistryworld/2013/02/octreolin-octreotide  ] using (octreotide, novartis)
• ritalin
• SEAL @241 (99.2%) on 22-apr-2011 [ 1 2 3 4 5 6 7 ] using (ritalin, novartis)
• CPL @1094 (75.0%) on 01-jan-2018 [ "arg1 lawsuits were filed against arg2" "arg1 class action lawsuits against arg2" ] using (ritalin, novartis)
• sandostatin
• SEAL @221 (100.0%) on 18-mar-2011 [ 1 ] using (sandostatin, novartis)
• starlix
• SEAL @224 (93.8%) on 24-mar-2011 [ 1 2 3 4 ] using (starlix, novartis)
• CPL @1105 (50.0%) on 25-mar-2018 [ "arg2 receives FDA approval for arg1" ] using (starlix, novartis)
• syntocinon
• SEAL @598 (50.0%) on 19-jun-2012 [ 1 ] using (syntocinon, novartis)
• tegretol
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 ] using (tegretol, novartis)
• OE @799 (100.0%) on 25-dec-2013 [ http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.drugs.com/answers/anyone-experiencing-trouble-tegretol-200-mg-527672.html https://www.epilepsy.org.uk/news/drugwatch/tegretol-products http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.pscard.com/index.cfm/patient-assistance-program/tegretol-to-zyvox/tegretol-xr-patient-assistance/ http://www.drugs.com/answers/anyone-experiencing-trouble-tegretol-200-mg-527672.html  ] using (tegretol, novartis)
• tegretol_chewable
• OE @877 (100.0%) on 09-oct-2014 [  ] using (tegretol_chewable, novartis)
• SEAL @611 (100.0%) on 09-jul-2012 [ 1 ] using (tegretol_chewable, novartis)
• tegretol_xr
• OE @877 (100.0%) on 09-oct-2014 [ http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152631.htm  ] using (tegretol_xr, novartis)
• SEAL @241 (100.0%) on 22-apr-2011 [ 1 ] using (tegretol_xr, novartis)
• tekturna
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (tekturna, novartis)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is manufactured by arg2" ] using (tekturna, novartis)
• tofranil
• SEAL @349 (93.8%) on 14-jul-2011 [ 1 2 3 4 ] using (tofranil, novartis)
• trileptal
• OE @806 (100.0%) on 23-jan-2014 [   ] using (trileptal, novartis)
• CPL @1094 (50.0%) on 01-jan-2018 [ "arg1 is a drug manufactured by arg2" ] using (trileptal, novartis)
• SEAL @236 (100.0%) on 16-apr-2011 [ 1 ] using (trileptal, novartis)
• xolair
• OE @1091 (100.0%) on 27-dec-2017 [ https://www.gene.com/media/press-releases/5707/2002-12-18/genentech-and-novartis-submit-amendment- https://www.gene.com/media/press-releases/14551/2013-10-10/fda-files-genentechs-supplemental-biolog https://www.gene.com/media/press-releases/5707/2002-12-18/genentech-and-novartis-submit-amendment-  ] using (xolair, novartis)
• SEAL @269 (87.5%) on 24-may-2011 [ 1 2 3 ] using (xolair, novartis)
• zelnorm
• CPL @1105 (87.5%) on 25-mar-2018 [ "arg2 showed that patients taking arg1" "arg2 plans to recall arg1" "arg2 under the trade names arg1" ] using (zelnorm, novartis)
• SEAL @224 (87.5%) on 24-mar-2011 [ 1 2 3 ] using (zelnorm, novartis)
• zometa
• CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 under the brand name arg1" "arg2 under the trade names arg1" "arg2 bone drug arg1" ] using (zometa, novartis)
• SEAL @221 (98.4%) on 18-mar-2011 [ 1 2 3 4 5 6 ] using (zometa, novartis)
• companyceo
• daniel_vasella
• CPL @1094 (99.8%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 chief arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• SEAL @212 (99.6%) on 19-feb-2011 [ 1 2 3 4 5 6 7 8 ] using (daniel_vasella, novartis)
• competeswith
• nestle
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (nestle, novartis)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (novartis, nestle)
• OE @823 (100.0%) on 17-mar-2014 [   ] using (nestle, novartis)
• phillip_morris_international
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (novartis, philip_morris)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentcollaborateswithagent,concept:proxyfor,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentcontrols,concept:competeswith" "Y~_X0~concept:agentcollaborateswithagent,concept:agentleadsorganization,concept:competeswith" "Y~_X0~concept:worker,concept:proxyfor,concept:competeswith" "Y~_X0~concept:organizationhasperson,concept:proxyfor,concept:competeswith" ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (novartis, philip_morris)
• SEAL @631 (100.0%) on 07-sep-2012 [ 1 ] using (philip_morris, novartis)
• OE @952 (93.9%) on 03-oct-2015 [ http://www.temis.com/mission http://www.emoocs2014.eu/node/32 http://www.unige.ch/medecine/frontiers-in-biomedicine/Peitsch.html  ] using (philip_morris, novartis)
• telegraph
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (novartis, telegraph)
• CPL @1103 (87.5%) on 06-mar-2018 [ "arg2 and Daily arg1" "arg2 and the Daily arg1" "arg2 and The Daily arg1" ] using (telegraph, novartis)
• controlledbyagent
• daniel_vasella
• SEAL @359 (87.5%) on 23-jul-2011 [ 1 2 3 ] using (daniel_vasella, novartis)
• CPL @1094 (93.8%) on 01-jan-2018 [ "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @1028 (85.1%) on 23-nov-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• mutualproxyfor
• daniel_vasella
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (novartis, daniel_vasella)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (novartis, daniel_vasella)
• SEAL @566 (75.0%) on 12-may-2012 [ 1 2 ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:superpartof" "Y~X0~concept:superpartof" "Y~_X0~concept:superpartof,concept:subpartof,concept:superpartof" "Y~X0~concept:controlledbyagent" "Y~X0~concept:agentcontrols,concept:mutualproxyfor,concept:agentcontrols" ] using (daniel_vasella, novartis)
• CPL @1100 (50.0%) on 31-jan-2018 [ "arg1 chairman arg2" ] using (novartis, daniel_vasella)
• organizationhasagent
• daniel_vasella
• CPL @1094 (99.2%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:proxyfor" "Y~_X0~concept:proxyfor,concept:controlledbyagent,concept:proxyfor" "Y~_X0~concept:agentcontrols,concept:mutualproxyfor,concept:proxyfor" "Y~X0~concept:agentcontrols,concept:agentcollaborateswithagent,concept:agentinteractswithagent" "Y~_X0~concept:proxyfor,concept:mutualproxyfor,concept:proxyfor" ] using (daniel_vasella, novartis)
• OE @1009 (90.2%) on 30-jul-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• organizationhasperson
• daniel_vasella
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:mutualproxyfor" "Y~_X0~concept:proxyfor" ] using (daniel_vasella, novartis)
• CPL @1094 (99.2%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• organizationhastopmember
• daniel_vasella
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• organizationleadbyperson
• daniel_vasella
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~_X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyperson,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:organizationleadbyagent,concept:personbelongstoorganization" "Y~X0~concept:personbelongstoorganization,concept:proxyof,concept:personbelongstoorganization" ] using (daniel_vasella, novartis)
• SEAL @214 (100.0%) on 22-feb-2011 [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ] using (daniel_vasella, novartis)
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @959 (99.3%) on 04-nov-2015 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• proxyof
• daniel_vasella
• CPL @1097 (93.8%) on 19-jan-2018 [ "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)
• OE @1028 (100.0%) on 23-nov-2016 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• SEAL @551 (75.0%) on 10-apr-2012 [ 1 2 ] using (daniel_vasella, novartis)
• superpartoforganization
• chiron
• CPL @1097 (93.8%) on 19-jan-2018 [ "arg1 is being acquired by arg2" "arg1 Corporation by arg2" "arg1 was subsequently acquired by arg2" "arg1 was acquired by arg2" ] using (chiron, novartis)
• worker
• daniel_vasella
• PRA @960 (100.0%) on 10-nov-2015 [ "Y~X0~concept:personleadsorganization,concept:worker,concept:agentleadsorganization" "Y~_X0~concept:agentleadsorganization" "Y~_X0~concept:agentrepresentsorganization" "Y~_X0~concept:personleadsorganization" "Y~_X0~concept:agentcontrols" ] using (daniel_vasella, novartis)
• OE @883 (100.0%) on 30-oct-2014 [ http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784 http://www.globalpost.com/dispatch/news/business/companies/130219/daniel-vasella-novartis-chairman-denied-779m-payout http://www.novartis.com/newsroom/media-releases/en/2013/1679194.shtml http://www.swissinfo.ch/eng/business/Daniel_Vasella_superhero_or_fat_cat.html?cid=34811784  ] using (daniel_vasella, novartis)
• CPL @1094 (99.6%) on 01-jan-2018 [ "arg2 President and Chief Executive Officer arg1" "arg2 Chairman and Chief Executive arg1" "arg2 Chairman and CEO arg1" "arg2 chairman arg1" "arg2 Chair and CEO arg1" "arg2 chief executive arg1" "arg2 chairman and chief executive arg1" "arg2 chairman and CEO arg1" ] using (daniel_vasella, novartis)